Protagonist Therapeutics (PTGX) announced positive topline results from its collaboration with Johnson & Johnson (JNJ), in ICONIC-LEAD1 and ICONIC-TOTAL2, two pivotal Phase 3 investigational studies ...
Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...
The pivotal Phase 3 ICONIC clinical development program of icotrokinra (JNJ-2113) in adult and pediatric patients 12 years of age and older with moderate-to-severe plaque PsO was initiated with two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback